Celadon is this morning delighted to announce its admission to the London Stock Exchange AIM market, raising £8.5m and bringing the total raise in the past year to ~£20m. Our goal is to become the provider and partner of choice for researching and producing pharmaceutical-grade cannabinoid-based medicines. We have built an integrated supply chain and …
Input your search keywords and press Enter.